Lupus Nephritis - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 108 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Lupus Nephritis - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Lupus Nephritis - Pipeline Review, H1 2015', provides an overview of the Lupus Nephritis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lupus Nephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lupus Nephritis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lupus Nephritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Lupus Nephritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Lupus Nephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Lupus Nephritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Lupus Nephritis Overview 8
Therapeutics Development 9
Pipeline Products for Lupus Nephritis - Overview 9
Pipeline Products for Lupus Nephritis - Comparative Analysis 10
Lupus Nephritis - Therapeutics under Development by Companies 11
Lupus Nephritis - Therapeutics under Investigation by Universities/Institutes 12
Lupus Nephritis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Lupus Nephritis - Products under Development by Companies 16
Lupus Nephritis - Products under Investigation by Universities/Institutes 17
Lupus Nephritis - Companies Involved in Therapeutics Development 18
AbbVie Inc. 18
Azano Pharmaceuticals Inc. 19
Biogen, Inc. 20
Bristol-Myers Squibb Company 21
Deltanoid Pharmaceuticals Inc. 22
F. Hoffmann-La Roche Ltd. 23
FibroStatin SL 24
GlaxoSmithKline plc 25
Invion Limited 26
Kadmon Corporation, LLC 27
Millennium Pharmaceuticals, Inc. 28
Teva Pharmaceutical Industries Limited 29
Zyrnat Biotherapeutics SL 30
Lupus Nephritis - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
abatacept (recombinant) - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
belimumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
BIIB-023 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
DP-001 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
FSMAB-26 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
INV-103 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ixazomib citrate - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
KD-025 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
laquinimod sodium - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Monoclonal Antibody for Lupus Nephritis - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
P-Dex - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
RO-5461111 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
venetoclax - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
voclosporin - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Y-175L - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
ZY-11 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Lupus Nephritis - Recent Pipeline Updates 74
Lupus Nephritis - Dormant Projects 98
Lupus Nephritis - Discontinued Products 100
Lupus Nephritis - Product Development Milestones 101
Featured News & Press Releases 101
Mar 30, 2015: Aurinia Highlights Initiation of Its Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers 101
Feb 09, 2015: Aurinia Pharmaceuticals to Initiate an Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers 101
Dec 11, 2014: Kadmon Corporation's KD025 Named a Top Priority Lupus Treatment Candidate by the Alliance for Lupus Research and the Lupus Research Institute 101
Jun 26, 2014: Aurinia Pharmaceuticals Initiates Phase 2b Clinical Trial of Voclosporin to Treat Lupus Nephritis 102
May 05, 2014: Possible Treatment for Kidney Disease in Lupus Studied at UH 102
May 05, 2014: Kadmon Corporation Presents Results of KD025 Preclinical and Clinical Studies at AAI Annual Meeting 104
Feb 07, 2014: Researchers Exploring Treatment For Lupus-Based Kidney Disease 104
Oct 15, 2013: Kadmon Announces Development Plans for Selective ROCK 2 Inhibitor, KD025, in Psoriasis, Lupus Nephritis and NASH 105
Jun 12, 2013: Teva And Active Biotech Report Positive Results From Phase IIa Study Of Laquinimod In Active Lupus Nephritis 106
Appendix 107
Methodology 107
Coverage 107
Secondary Research 107
Primary Research 107
Expert Panel Validation 107
Contact Us 107
Disclaimer 108

List of Tables

Number of Products under Development for Lupus Nephritis, H1 2015 9
Number of Products under Development for Lupus Nephritis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Lupus Nephritis - Pipeline by AbbVie Inc., H1 2015 18
Lupus Nephritis - Pipeline by Azano Pharmaceuticals Inc., H1 2015 19
Lupus Nephritis - Pipeline by Biogen, Inc., H1 2015 20
Lupus Nephritis - Pipeline by Bristol-Myers Squibb Company, H1 2015 21
Lupus Nephritis - Pipeline by Deltanoid Pharmaceuticals Inc., H1 2015 22
Lupus Nephritis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 23
Lupus Nephritis - Pipeline by FibroStatin SL, H1 2015 24
Lupus Nephritis - Pipeline by GlaxoSmithKline plc, H1 2015 25
Lupus Nephritis - Pipeline by Invion Limited, H1 2015 26
Lupus Nephritis - Pipeline by Kadmon Corporation, LLC, H1 2015 27
Lupus Nephritis - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 28
Lupus Nephritis - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 29
Lupus Nephritis - Pipeline by Zyrnat Biotherapeutics SL, H1 2015 30
Assessment by Monotherapy Products, H1 2015 31
Number of Products by Stage and Target, H1 2015 33
Number of Products by Stage and Mechanism of Action, H1 2015 35
Number of Products by Stage and Route of Administration, H1 2015 37
Number of Products by Stage and Molecule Type, H1 2015 39
Lupus Nephritis Therapeutics - Recent Pipeline Updates, H1 2015 74
Lupus Nephritis - Dormant Projects, H1 2015 98
Lupus Nephritis - Dormant Projects (Contd..1), H1 2015 99
Lupus Nephritis - Discontinued Products, H1 2015 100